Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 10/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 7/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 6/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 5/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | DRD5 | P21918 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | GMNN | O75496 | 1/20 | 0.64 |
| ▸ | APEX1 | P27695 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462268 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL30553076 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL10515842 | 0.99 | CHRM2 (0.98) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8880388 | 0.90 | CHRM2 (0.82) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8910637 | 0.90 | CHRM2 (0.82) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL9727679 | 0.90 | CHRM2 (0.82) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL12648694 | 0.89 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL10516759 | 0.89 | CHRM2 (0.80) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8880810 | 0.89 | CHRM2 (0.80) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8881259 | 0.89 | CHRM2 (0.80) | CHRM2CHRM1CHRM3CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180360845-A1 | MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-12-20 | — | — | US | claimed |
| EP-0634932-B1 | METHOD FOR REDUCING INTRAOCULAR PRESSURE IN THE MAMMALIAN EYE BY ADMINISTRATION OF MUSCARINIC ANTAGONISTS | ALLERGAN INC (US) | 2002-06-19 | — | — | EP | claimed |
| US-20230364104-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF HUMAN HYPOCHOLINERGIC DISORDERS | CLARENCE SMITH KATHLEEN E (US) | 2023-11-16 | — | — | US | disclosed |
| US-20180360845-A1 | MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-12-20 | — | — | US | disclosed |
| US-5641772-A | Condensed diazepinones, processes for preparing them and agents containing these compounds for treating diseases of the central nervous system and for promoting cerebral blood circulation | DR. KARL THOMAE GMBH (DE) | 1997-06-24 | — | — | US | disclosed |
| US-5610155-A | ALZHEIMER'S | DR. KARL THOMAE GMBH (DE) | 1997-03-11 | — | — | US | disclosed |
| EP-0508370-B1 | Condensed diazepinones, process for their preparation and compositions containing them for the treatment of the central nervous system and to enhance cerebral perfusion | THOMAE GMBH DR K (DE) | 1996-07-03 | — | — | EP | disclosed |
| US-5175158-A | CONDENSED DIAZEPINONES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | DR. KARL THOMAE, GMBH (DE) | 1992-12-29 | — | — | US | disclosed |
| EP-0508370-A1 | Condensed diazepinones, process for their preparation and compositions containing them for the treatment of the central nervous system and to enhance cerebral perfusion | Dr. Karl Thomae GmbH (DE) | 1992-10-14 | — | — | EP | disclosed |
| EP-0402734-A2 | Composition for the treatment of application of the central nervous system and to enhance cerebral perfusion | Dr. Karl Thomae GmbH (DE) | 1990-12-19 | — | — | EP | disclosed |
| EP-0312895-A2 | Condensed diazepinones, process for their preparation and medicament containing them | Dr. Karl Thomae GmbH (DE) | 1989-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364104-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF HUMAN HYPOCHOLINERGIC DISORDERS | CHRM1, CHRM2, CHRM4 | CHRM2 2/4885CHRM1 1/4885CHRM3 4/4885 |
| US-20180360845-A1 | MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS | CHRM2, CHRM1, CHRM4 | CHRM2 1/4885CHRM1 2/4885CHRM3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.